Ace­lyrin crew be­hind first thy­roid eye dis­ease med­i­cine builds its po­ten­tial com­peti­tor, with ear­ly da­ta to boast

Im­munol­o­gy biotech Ace­lyrin an­nounced Wednes­day morn­ing that its ex­per­i­men­tal thy­roid eye dis­ease treat­ment im­proved symp­toms in a small hand­ful of pa­tients as part of an ear­ly-stage clin­i­cal tri­al.

The drug, though in ear­ly de­vel­op­ment, could one day com­pete with Te­pez­za, which in 2020 be­came the first med­i­cine ap­proved to treat the au­toim­mune eye dis­ease and has grown in­to a bil­lion dol­lar-plus med­i­cine. But un­like Te­pez­za, which is giv­en as an in­fu­sion, Ace­lyrin’s ex­per­i­men­tal an­ti­body lonigutam­ab comes as an in­jec­tion and could make get­ting treat­ment eas­i­er for pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER